Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia
| Autor: | Karl Zilles, Andreas Matusch, David Maintz, Mohammad Maarouf, Theo O.J. Gruendler, Jens Kuhn, Jens Wiltfang, K. Hardenacke, H.-J. Freund, Christiane Woopen, Volker Sturm, Andreas Bauer, P. Häussermann, Doris Lenartz, Christian Bührle, Martin Hellmich, R.-J. Schulz, C Bartsch, Jürgen K. Mai, Joachim Klosterkötter, Markus Ullsperger, Michaela Noreik |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Deep brain stimulation Deep Brain Stimulation medicine.medical_treatment Neuropsychological Tests Electroencephalography Biologische psychologie Nucleus basalis 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Alzheimer Disease Fluorodeoxyglucose F18 Neuroplasticity medicine Humans Cholinergic neuron Molecular Biology Aged 030304 developmental biology Psychiatric Status Rating Scales 0303 health sciences medicine.diagnostic_test Plasticity and Memory [DI-BCB_DCC_Theme 3] Middle Aged medicine.disease Magnetic Resonance Imaging Neuromodulation (medicine) 3. Good health Psychiatry and Mental health Treatment Outcome Basal Nucleus of Meynert Positron-Emission Tomography Anesthesia Forebrain Quality of Life Biological psychology Female Alzheimer's disease Psychology Neuroscience 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Molecular Psychiatry, 20, 353-360 Molecular Psychiatry, 20, 3, pp. 353-360 |
| ISSN: | 1476-5578 1359-4184 |
| DOI: | 10.1038/mp.2014.32 |
| Popis: | Item does not contain fulltext Cholinergic neurons of the medial forebrain are considered important contributors to brain plasticity and neuromodulation. A reduction of cholinergic innervation can lead to pathophysiological changes of neurotransmission and is observed in Alzheimer’s disease. Here we report on six patients with mild to moderate Alzheimer’s disease (AD) treated with bilateral low-frequency deep brain stimulation (DBS) of the nucleus basalis of Meynert (NBM). During a four-week double-blind sham-controlled phase and a subsequent 11-month follow-up open label period, clinical outcome was assessed by neuropsychological examination using the Alzheimer’s Disease Assessment Scale—cognitive subscale as the primary outcome measure. Electroencephalography and [18F]-fluoro-desoxyglucose positron emission tomography were, besides others, secondary endpoints. On the basis of stable or improved primary outcome parameters twelve months after surgery, four of the six patients were considered responders. No severe or non-transitional side effects related to the stimulation were observed. Taking into account all limitations of a pilot study, we conclude that DBS of the NBM is both technically feasible and well tolerated. 8 p. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|